How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,162 results for

SGLT2 Inhibitor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Efficacy and safety of SGLT2 inhibitors and incretin-based agents combination therapy versus SGLT2 inhibitors alone in patients with type 2 diabetes: a systematic review and meta-analysis

Efficacy and safety of SGLT2 inhibitors and incretin-based agents combination therapy versus SGLT2 inhibitors alone in patients with type 2 diabetes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

2. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. (PubMed)

Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. To develop a quantitative drug-disease systems model to investigate the paradox that sodium-glucose co-transporter (SGLT)2 is responsible for >80% of proximal tubule glucose reabsorption, yet SGLT2 inhibitor treatment results in only 30% to 50% less reabsorption in patients with type 2 (...) diabetes mellitus (T2DM).A physiologically based four-compartment model of renal glucose filtration, reabsorption and excretion via SGLT1 and SGLT2 was developed as a system of ordinary differential equations using R/IQRtools. SGLT2 inhibitor pharmacokinetics and pharmacodynamics were estimated from published concentration-time profiles in plasma and urine and from urinary glucose excretion (UGE) in healthy people and people with T2DM.The final model showed that higher renal glucose reabsorption

2019 obesity & metabolism

3. Randomised controlled trial: SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

Randomised controlled trial: SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease Article Text Therapeutics/Prevention Randomised controlled trial SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease André J Scheen

2017 Evidence-Based Medicine (Requires free registration)

4. SGLT2 Inhibitors and Diabetics: Does sugar in the pee protect thee?

SGLT2 Inhibitors and Diabetics: Does sugar in the pee protect thee? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,600 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) October 30, 2017 SGLT2 Inhibitors and Diabetics: Does sugar in the pee protect thee? Clinical Question: In patients with type 2 diabetes, do sodium-glucose co-transporter 2 (SGLT2) inhibitors affect mortality or cardiovascular disease (CVD)? Bottom-line: In diabetic patients at high-risk for CVD, empagliflozin reduces mortality for 1 in 39 patients at ~3 years (compared to placebo), while canagliflozin and empagliflozin both reduce CVD death, non-fatal myocardial infarction (MI), and stroke for ~1

2017 Tools for Practice

5. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER (PubMed)

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below-knee lower extremity (BKLE) amputation

Full Text available with Trip Pro

2018 obesity & metabolism

6. Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observ (PubMed)

Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observ 30136414 2019 01 11 1463-1326 21 2 2019 Feb Diabetes, obesity & metabolism Diabetes Obes Metab Comment on "Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure

2018 obesity & metabolism

7. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis

SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis To assess the efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta-analysis of 14 randomized controlled trials (RCTs) involving 4828 patients. Compared with a DPP-4 inhibitor, SGLT2 inhibitor/DPP-4 inhibitor combination (...) therapy was significantly associated with a decrease in glycaemic control (HbA1c, -0.71%; fasting plasma glucose [FPG], -25.62 mg/dL; postprandial plasma glucose, -44.00 mg/dL), body weight (-2.05 kg) and systolic blood pressure (-5.90 mm Hg), but an increase in total cholesterol (TC) of 3.24%, high-density lipoprotein of 6.15% and low-density lipoprotein of 2.55%. Adding a DPP-4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by -0.31%, FPG by -8.94 mg/dL, TC by -1.48% and triglycerides by -3.25

2018 EvidenceUpdates

8. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycaemic efficacy is dependent on kidney function. We performed a systematic review and meta-analysis to assess the efficacy and safety (...) of SGLT2 inhibitors in patients with T2DM and CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 .We searched MEDLINE, EMBASE and the Cochrane Library until 7 August 2018 and websites of the US, European and Japanese regulatory authorities until 27 July 2018 for data from randomized controlled trials of SGLT2 inhibitors that included reporting of effects on biomarkers, cardiovascular, renal or safety outcomes in individuals with T2DM and CKD. Random effects models

2019 EvidenceUpdates

9. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japanese (PubMed)

Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japanese We investigated the effects of SGLT2 inhibitors vs DPP4 inhibitors on renal function preservation using real-world data of patients with type 2 diabetes in Japan, and identified which subgroups of patients showed greater benefits on renal (...) function preservation with SGLT2 inhibitors vs DPP4 inhibitors.We retrospectively analysed claims data recorded in the Medical Data Vision database in Japan of patients with type 2 diabetes (aged ≥18 years) prescribed any SGLT2 inhibitor or any DPP4 inhibitor between May 2014 and September 2016 (identification period), in whom estimated glomerular filtration rate (eGFR) was measured at least twice (baseline, up to 6 months before the index date; follow-up: 9-15 months after the index date

2019 obesity & metabolism

10. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. (PubMed)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these effects over short- and long-term follow-up in patients with T2DM who were inadequately controlled with metformin (≥1500

2019 obesity & metabolism

11. Favorable effect of the SGLT2 inhibitor canagliflozin plus the DPP-4 inhibitor teneligliptin in combination on glycemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). (PubMed)

Favorable effect of the SGLT2 inhibitor canagliflozin plus the DPP-4 inhibitor teneligliptin in combination on glycemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). This multicentre, prospective, randomized, open-label, blinded-endpoint, parallel-group, short-term (4-5 weeks) controlled trial was conducted to investigate the superiority of the effect of reducing mean amplitude of glycaemic excursions (MAGE) during meal tolerance tests (...) (MTTs) for the combination of dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter-2 (SGLT2) inhibitor compared with SGLT2 inhibitor monotherapy. Ninety-nine patients with type 2 diabetes who were taking teneligliptin (20 mg/d) were randomized to one of the following two groups: those who switched to 100 mg/d of canagliflozin (SWITCH group) or those who added 100 mg/d of canagliflozin (COMB group). MAGE in the COMB group was significantly decreased compared

2019 obesity & metabolism

12. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. (PubMed)

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined.We did a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome

2018 Lancet

13. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis

SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on risk of stroke have not been conclusively established. Therefore, we conducted a meta-analysis to evaluate the effects of SGLT2 inhibitors on stroke risk in patients with type 2 diabetes mellitus (T2DM) by searching available randomized trials in PubMed, Embase, CENTRAL, Web of Science, Scopus and ClinicalTrials.gov (...) databases. We identified 32 eligible trials involving 75 540 participants. The incidence of stroke in groups receiving SGLT2 inhibitor monotherapy or combination therapy did not differ significantly from that in control groups, with a relative risk (RR) of 1.01 and 1.0, respectively. Three SGLT2 inhibitors were tested, with similar RR values (canagliflozin [RR, 0.91], dapagliflozin [RR, 0.99] and empagliflozin [RR, 1.03]). Subgroup analyses showed that RR values were not affected by gender, age

2018 EvidenceUpdates

14. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials. (PubMed)

Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials. Objective To assess the efficiency and safety of a novel sodium-glucose co-transporter 2 (SGLT2) inhibitor-SGLT2 inhibitors, in combination with insulin for type 1 diabetes mellitus (T1DM). Methods We searched Medline, Embase, and the Cochrane Collaboration Library to identify the eligible studies published between January 2010 and July 2016 without restriction of language (...) . The Food and Drug Administration (FDA) data and ClinicalTrials (http://www.clinicaltrials.gov) were also searched. The included studies met the following criteria: randomized controlled trials; T1DM patients aged between 18 and 65 years old; patients were treated with insulin plus SGLT2 inhibitors for more than 2 weeks; patients' glycosylated hemoglobin (HbA1c) levels were between 7% and 12%. The SGLT2 inhibitors group was treated with SGLT2 inhibitors plus insulin, and the placebo group received

2017 Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih

15. Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality (PubMed)

Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality A favorable effect of an inhibitor of the sodium-glucose cotransporter 2 (SGLT2i) on mortality of diabetic patients was recently reported, although mechanisms underlying that effect remained unclear. Here, we examine SGLT2i effects on survival of diabetic mice and assess factors underlying these outcomes. To examine SGLT2i treatment effects in a model of severe diabetes, we fed

Full Text available with Trip Pro

2017 NPJ aging and mechanisms of disease

16. The effects of SGLT2 inhibitors on major kidney outcomes in patients with type 2 diabetes: a systematic review and meta-analysis

The effects of SGLT2 inhibitors on major kidney outcomes in patients with type 2 diabetes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

17. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other antidiabetics in patients with type 2 diabetes mellitus to prevent cardiovascular events. Systematic review protocol

SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other antidiabetics in patients with type 2 diabetes mellitus to prevent cardiovascular events. Systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

18. Effect of sodium glucose co-transporter 2 (SGLT2) inhibitors for renal outcomes in diabetes mellitus: a systematic review and meta-analysis

Effect of sodium glucose co-transporter 2 (SGLT2) inhibitors for renal outcomes in diabetes mellitus: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

19. SGLT2 inhibitors for type 2 diabetes mellitus in adults

SGLT2 inhibitors for type 2 diabetes mellitus in adults Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

20. SGLT2 inhibitors and renal outcomes in Type 2 Diabetes and nephropathy: a systematic review and meta-analysis of randomized controlled studies

SGLT2 inhibitors and renal outcomes in Type 2 Diabetes and nephropathy: a systematic review and meta-analysis of randomized controlled studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>